BCM
VIR icon

Bronte Capital Management’s Vir Biotechnology VIR Stock Holding History

Bronte Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-74,920
Closed -$3.26M – 30
2021
Q3 		$3.26M Buy
+74,920
New +$3.24M 0.24% 23

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Bronte Capital Management's VIR Position: Q4 2021 in Review

Bronte Capital Management sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 74,920 shares — an estimated $3.26M sold.

Bronte Capital Management first reported a position in VIR in Q3 2021 and held it in 1 quarter. The position peaked at $3.26M in Q3 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

  • Bronte Capital Management reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Bronte Capital Management sold 74,920 Vir Biotechnology shares in Q4 2021, an estimated $3.26M.
  • Bronte Capital Management first reported a position in Vir Biotechnology in Q3 2021 and held it in 1 quarter.
  • Bronte Capital Management's Vir Biotechnology position peaked at $3.26M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on Bronte Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.